Progress in Cardiovascular Diseases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Evidence-Based Exercise Recommendations to Reduce Hepatic Fat Content in Youth- a Systematic Review and Meta-Analysis
The main purposes of this study were to elucidate the effects of supervised-exercise training (ET) interventions on hepatic fat content and on non-alcoholic fatty liver disease (NAFLD) prevalence in children and adolescents and to provide information about the optimal ET prescription (type, intensity, volume, and frequency) needed to reduce hepatic fat content in youths. Supervised-ET interventions performed in children and adolescents (6 –19 years) that provided results of exercise effects on hepatic fat content or NAFLD prevalence were included. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - February 13, 2018 Category: Cardiology Authors: Mar ía Medrano, Cristina Cadenas-Sanchez, Celia Álvarez-Bueno, Iván Cavero-Redondo, Jonatan R. Ruiz, Francisco B. Ortega, Idoia Labayen Source Type: research

Effect of High Intensity Interval Training on Cardiac Function in Children with Obesity: a Randomised Controlled Trial
High intensity interval training (HIIT) confers superior cardiovascular health benefits to moderate intensity continuous training (MICT) in adults and may be efficacious for improving diminished cardiac function in obese children. The aim of this study was to compare the effects of HIIT, MICT and nutrition advice interventions on resting left ventricular (LV) peak systolic tissue velocity (S ′) in obese children. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - February 13, 2018 Category: Cardiology Authors: Charlotte B. Ingul, Katrin A. Dias, Arnt E. Tjonna, Turid Follestad, Mansoureh S. Hosseini, Anita S. Timilsina, Siri M. Hollekim-Strand, Torstein B. Ro, Peter S.W. Davies, Peter A. Cain, Gary M. Leong, Jeff S. Coombes Source Type: research

Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician
Determining the optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention is a complex decision. Randomized controlled trials have shown that while shorter durations of DAPT may lower the risk of bleeding, longer durations of DAPT can reduce the risk of late stent thrombosis and ischemia-related events. In this review article, we will discuss the current guidelines, review contemporary trial data that have evaluated short and extended durations of DAPT, and address common clinical questions. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Mahesh K. Vidula, Eric A. Secemsky, Robert W. Yeh Source Type: research

Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percutaneous coronary intervention (PCI). However, approximately 10% of these patients have concomitant atrial fibrillation (AF) and require chronic oral anticoagulant (OAC) in addition to DAPT. This traditional “triple therapy” has been associated with a three to four-fold increased risk of bleeding. The safety of non-vitamin K OAC (NOAC)-based strategies, using a NOAC plus a P2Y12 inhibitor, has been compared to vitamin K antagonist (VKA)-based triple therapy in the PIONEER AF-PCI and REDUAL PCI rando mized ...
Source: Progress in Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Mathieu Kerneis, Usama Talib, Tarek Nafee, Yazan Daaboul, Seyedmahdi Pahlavani, Anmol Pitliya, M.M. Furqan, Sudarshana Datta, Hassan A. Kazmi, Ahmed Younes, C. Michael Gibson Source Type: research

Duration of dual antiplatelet therapy for stented patients: An update for the clinician
Determining the optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention is a complex decision. Randomized controlled trials have shown that while shorter durations of DAPT may lower the risk of bleeding, longer durations of DAPT can reduce the risk of late stent thrombosis and ischemia-related events. In this review article, we will discuss the current guidelines, review contemporary trial data that have evaluated short and extended durations of DAPT, and address common clinical questions. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Mahesh K. Vidula, Eric A. Secemsky, Robert W. Yeh Source Type: research

Triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percutaneous coronary intervention (PCI). However, approximately 10% of these patients have concomitant atrial fibrillation (AF) and require chronic oral anticoagulant (OAC) in addition to DAPT. This traditional “triple therapy” has been associated with a three to four-fold increased risk of bleeding. The safety of non-vitamin K OAC (NOAC)-based strategies, using a NOAC plus a P2Y12 inhibitor, has been compared to vitamin K antagonist (VKA)-based triple therapy in the PIONEER AF-PCI and REDUAL PCI rando mized ...
Source: Progress in Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Mathieu Kerneis, Usama Talib, Tarek Nafee, Yazan Daaboul, Seyedmahdi Pahlavani, Anmol Pitliya, M.M. Furqan, Sudarshana Datta, Hassan A. Kazmi, Ahmed Younes, C. Michael Gibson Source Type: research

Thiamine and Cardiovascular Disease: A Literature Review
This article aims to provide a review of current literature on the role of thiamine in the human body, the current scope of thiamine deficiency, and explore the specific effects of thiamine deficiency and supplementation on the cardiovascular system. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 21, 2018 Category: Cardiology Authors: James J. DiNicolantonio, Jing Liu, James H. O'Keefe Source Type: research

Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy – “Real World” Experience
Atrial fibrillation (AF) is a common arrhythmia that increases in prevalence with advancing age and in patients with coronary artery disease, revascularization, particularly with percutaneous coronary intervention (PCI), is also common. Both disease states have thrombosis as a core pathophysiologic process which requires treatment – low sheer stress thrombi in AF and intracoronary high sheer stress thrombi in PCI. For the 10–20% of patients who have both AF and undergo PCI, preventing thrombotic complications will require inhibition of both processes requiring simultaneous use of anticoagulation and antiplatelet therap...
Source: Progress in Cardiovascular Diseases - January 21, 2018 Category: Cardiology Authors: Mark B. Effron, C. Michael Gibson Source Type: research

The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease – Where Is the Moon Now?
Since the early 1900s, thrombosis has been known to play a major role in cardiovascular disease (CVD). Herrick1 first described total coronary occlusion in patients with sudden death or acute myocardial infarction (AMI). In the 1950s –60s, use of warfarin patients with AMI was instituted.2 By time the 1970s were almost over, significant controversy ensued over the quality of the clinical trials which weighed heavily in support for their positive findings.3–5 The first large trials of aspirin therapy began to come forward dur ing the late 1970s demonstrating that the use of aspirin would prevent recurrent AMI. (Source: ...
Source: Progress in Cardiovascular Diseases - January 21, 2018 Category: Cardiology Authors: Mark B. Effron, C. Michael Gibson Tags: Editorial Source Type: research

The waxing and waning of antithrombotic therapy in cardiovascular disease – Where is the moon now?
Since the early 1900s, thrombosis has been known to play a major role in cardiovascular disease (CVD). Herrick1 first described total coronary occlusion in patients with sudden death or acute myocardial infarction (AMI). In the 1950s –60s, use of warfarin patients with AMI was instituted.2 By time the 1970s were almost over, significant controversy ensued over the quality of the clinical trials which weighed heavily in support for their positive findings.3–5 The first large trials of aspirin therapy began to come forward dur ing the late 1970s demonstrating that the use of aspirin would prevent recurrent AMI . (Source:...
Source: Progress in Cardiovascular Diseases - January 21, 2018 Category: Cardiology Authors: Mark B. Effron, C. Michael Gibson Source Type: research

Thiamine and cardiovascular disease: A literature review
This article aims to provide a review of current literature on the role of thiamine in the human body, the current scope of thiamine deficiency, and explore the specific effects of thiamine deficiency and supplementation on the cardiovascular system. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 21, 2018 Category: Cardiology Authors: James J. DiNicolantonio, Jing Liu, James H. O'Keefe Source Type: research

Dual (anticoagulant plus single antiplatelet) vs triple (anticoagulant plus dual antiplatelet) antithrombotic therapy – “Real world” experience
Atrial fibrillation (AF) is a common arrhythmia that increases in prevalence with advancing age and in patients with coronary artery disease, revascularization, particularly with percutaneous coronary intervention (PCI), is also common. Both disease states have thrombosis as a core pathophysiologic process which requires treatment – low sheer stress thrombi in AF and intracoronary high sheer stress thrombi in PCI. For the 10–20% of patients who have both AF and undergo PCI, preventing thrombotic complications will require inhibition of both processes requiring simultaneous use of anticoagulation and antiplatelet therap...
Source: Progress in Cardiovascular Diseases - January 21, 2018 Category: Cardiology Authors: Mark B. Effron, C. Michael Gibson Source Type: research

Clinical Implications of Technological Advances in Screening for Atrial Fibrillation
The incidence of atrial fibrillation (AF) continues to increase worldwide as people live longer. AF is the leading cause of stroke among patients older than 75  years and is responsible for at least 15% of all strokes. Industry has responded to this problem with a plethora of monitoring devices. These include single lead ECG adhesive sensors, implantable loop recorders, smartphone attachments and wearables. This review will concentrate on clinical studie s using these technologies. There are wearables including watches and watch-like devices that will be mentioned but these have not been validated for clinical use. (Sour...
Source: Progress in Cardiovascular Diseases - January 15, 2018 Category: Cardiology Authors: Nikhil Singh, Sung Chun, David Hadley, Victor Froelicher Source Type: research

Clinical implications of technological advances in screening for atrial fibrillation
The incidence of atrial fibrillation (AF) continues to increase worldwide as people live longer. AF is the leading cause of stroke among patients older than 75  years and is responsible for at least 15% of all strokes. Industry has responded to this problem with a plethora of monitoring devices. These include single lead ECG adhesive sensors, implantable loop recorders, smartphone attachments and wearables. This review will concentrate on clinical studie s using these technologies. There are wearables including watches and watch-like devices that will be mentioned but these have not been validated for clinical use. (Sour...
Source: Progress in Cardiovascular Diseases - January 15, 2018 Category: Cardiology Authors: Nikhil Singh, Sung Chun, David Hadley, Victor Froelicher Source Type: research

The Timing of P2Y12 Inhibitor Initiation in the Treatment of ACS? Does the Evidence Exist in This Era?
The majority of acute coronary syndromes (ACS) are well characterized as a consequence of plaque rupture and subsequent thrombosis. Antiplatelet agents targeting inhibition of P2Y12 receptors on the platelets have been shown to reduce future risk of cardiovascular events in this patient population. However, the timing of initiation of these agents, in particular, in patients managed with an invasive strategy with percutaneous coronary interventions (PCI) is debatable. The data supporting pretreatment with antiplatelet agents prior to PCI in ACS patients date to trials performed>15  years ago, wherein the time to PCI was>...
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Harsh Golwala, Deepak L. Bhatt Source Type: research